Neonatal hyperthyroidism in an extremely low birth weight infant born to a mother with Graves' disease.

IF 1.2 Q4 ENDOCRINOLOGY & METABOLISM
Clinical Pediatric Endocrinology Pub Date : 2025-10-01 Epub Date: 2025-08-08 DOI:10.1297/cpe.2025-0001
Daly Pen, Kimyi Phou, Sokuntheavy Ly, Rathmony Heng, Sakviseth Bin, Sethikar Im
{"title":"Neonatal hyperthyroidism in an extremely low birth weight infant born to a mother with Graves' disease.","authors":"Daly Pen, Kimyi Phou, Sokuntheavy Ly, Rathmony Heng, Sakviseth Bin, Sethikar Im","doi":"10.1297/cpe.2025-0001","DOIUrl":null,"url":null,"abstract":"<p><p>Neonatal hyperthyroidism (NH) mostly commonly occurs in infants born to mothers with Graves' disease. NH in extremely low birth weight (ELBW) infants has been rarely described. Here, we report a case of NH in an infant born at 29 wk 6 d of gestation with a birth weight of 825 g. The mother had untreated Graves' disease during pregnancy. During the 2<sup>nd</sup> wk of life, the infant developed persistent tachycardia (heart rate > 160 beats per min). Diagnosis of NH was made according to the results of her thyroid function: thyroid-stimulating hormone,< 0.005 mU/L (Reference range: 0.8-12.0 mU/L); free triiodothyronine, 5.1 pg/mL (Reference range: 2.3-4.2 pg/mL); free thyroxine, 38.5 pmol/L (Reference range: 10-33 pmol/L); and thyroid-stimulating hormone receptor antibody, 7.6 IU/L (Reference range: ≤ 1.22 IU/L). Carbimazole was administered. After 1 wk of treatment, levothyroxine was added due to a rapid decline in thyroid function. The treatment regimen was adjusted to achieve normal thyroid function. Her heart rate normalized with no significant hemodynamic instability or long-term complications during her hospitalization or follow-up visits. NH should be considered in ELBW infants with a maternal history of Graves' disease who present with persistent tachycardia. Monitoring thyroid function may be required more closely in ELBW infants when NH management is administered.</p>","PeriodicalId":10678,"journal":{"name":"Clinical Pediatric Endocrinology","volume":"34 4","pages":"264-267"},"PeriodicalIF":1.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12494402/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pediatric Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1297/cpe.2025-0001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/8 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Neonatal hyperthyroidism (NH) mostly commonly occurs in infants born to mothers with Graves' disease. NH in extremely low birth weight (ELBW) infants has been rarely described. Here, we report a case of NH in an infant born at 29 wk 6 d of gestation with a birth weight of 825 g. The mother had untreated Graves' disease during pregnancy. During the 2nd wk of life, the infant developed persistent tachycardia (heart rate > 160 beats per min). Diagnosis of NH was made according to the results of her thyroid function: thyroid-stimulating hormone,< 0.005 mU/L (Reference range: 0.8-12.0 mU/L); free triiodothyronine, 5.1 pg/mL (Reference range: 2.3-4.2 pg/mL); free thyroxine, 38.5 pmol/L (Reference range: 10-33 pmol/L); and thyroid-stimulating hormone receptor antibody, 7.6 IU/L (Reference range: ≤ 1.22 IU/L). Carbimazole was administered. After 1 wk of treatment, levothyroxine was added due to a rapid decline in thyroid function. The treatment regimen was adjusted to achieve normal thyroid function. Her heart rate normalized with no significant hemodynamic instability or long-term complications during her hospitalization or follow-up visits. NH should be considered in ELBW infants with a maternal history of Graves' disease who present with persistent tachycardia. Monitoring thyroid function may be required more closely in ELBW infants when NH management is administered.

新生儿甲状腺功能亢进在极低出生体重婴儿出生的母亲与格雷夫斯病。
新生儿甲状腺功能亢进(NH)最常见于Graves病母亲所生的婴儿。极低出生体重(ELBW)婴儿的NH很少被描述。在这里,我们报告一例新生儿NH出生在29周妊娠6天,出生体重为825克。这位母亲在怀孕期间患有未经治疗的格雷夫斯病。在出生后的第二周,婴儿出现持续性心动过速(心率为每分钟160次)。根据甲状腺功能检查结果诊断为NH:促甲状腺激素< 0.005 mU/L(参考范围:0.8-12.0 mU/L);游离三碘甲状腺原氨酸,5.1 pg/mL(参考范围:2.3-4.2 pg/mL);游离甲状腺素38.5 pmol/L(参考范围:10-33 pmol/L);促甲状腺激素受体抗体,7.6 IU/L(参考范围:≤1.22 IU/L)。给予卡咪唑。治疗1周后,由于甲状腺功能迅速下降,添加左旋甲状腺素。调整治疗方案,使甲状腺功能恢复正常。在住院或随访期间,患者心率正常,无明显血流动力学不稳定或长期并发症。母亲有格雷夫斯病病史并伴有持续性心动过速的新生儿应考虑NH。当实施NH治疗时,可能需要更密切地监测ELBW婴儿的甲状腺功能。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Pediatric Endocrinology
Clinical Pediatric Endocrinology ENDOCRINOLOGY & METABOLISM-
CiteScore
2.40
自引率
7.10%
发文量
34
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信